Bicyclic amides for enhancing glutamatergic synaptic responses

ABSTRACT

This invention relates to compounds, pharmaceutical compositions and methods for use in the prevention and treatment of cerebral insufficiency, including enhancement of receptor functioning in synapses in brain networks responsible for basic and higher order behaviors. These brain networks, which are involved in regulation of breathing, and cognitive abilities related to memory impairment, such as is observed in a variety of dementias, in imbalances in neuronal activity between different brain regions, as is suggested in disorders such as Parkinson&#39;s disease, schizophrenia, respiratory depression, sleep apneas, attention deficit hyperactivity disorder and affective or mood disorders, and in disorders wherein a deficiency in neurotrophic factors is implicated, as well as in disorders of respiration such as overdose of an alcohol, an opiate, an opioid, a barbiturate, an anesthetic, or a nerve toxin, or where the respiratory depression results form a medical condition such as central sleep apnea, stroke-induced central sleep apnea, obstructive sleep apnea, congenital hypoventilation syndrome, obesity hypoventilation syndrome, sudden infant death syndrome, Rett syndrome, spinal cord injury, traumatic brain injury, Cheney-Stokes respiration, Ondines curse, Prader-Willi&#39;s syndrome and drowning, hi a particular aspect, the invention relates to bicyclic amide compounds useful for treatment of such conditions, and methods of using these compounds for such treatment.

RELATED APPLICATIONS

This application claims the benefit of priority of International PatentApplication No. PCT/US2008/009508 filed Aug. 8, 2008 entitled “BICYCLICAMIDES FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES.”

PCT/US2008/009508 claims the benefit of priority of U.S. provisionalpatent application Ser. No. 60/964,362, filed Aug. 10, 2007 entitled“BICYCLIC AMIDES FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES,” theentire contents of which are incorporated by reference herein.

FIELD OF INVENTION

This invention relates to compounds, pharmaceutical compositions andmethods for use in the prevention and treatment of cerebralinsufficiency, including enhancement of receptor functioning in synapsesin brain networks responsible for various behaviors. These brainnetworks are involved in basic functions such as breathing, to morecomplex functions such as memory and cognition. Imbalances in neuronalactivities between different brain regions may lead to a number ofdisorders, including psychiatric and neurological disorders, includingmemory impairment, Parkinson's disease, schizophrenia, attention deficitand affective or mood disorders, respiratory depression and in disorderswherein a deficiency in neurotrophic factors is implicated. In aparticular aspect, the invention relates to compounds useful fortreatment of such conditions, and methods of using these compounds forsuch treatment.

BACKGROUND OF THE INVENTION

The release of glutamate at synapses at many sites in mammalianforebrain stimulates two classes of postsynaptic ionotropic glutamatereceptors. These classes are usually referred to as AMPA andN-methyl-D-aspartic acid (NMDA) receptors. AMPA receptors mediate avoltage independent fast excitatory post-synaptic current (the fastEPSC), whereas NMDA receptors generate a voltage-dependent, slowexcitatory current. Studies carried out in slices of hippocampus orcortex, indicate that the AMPA receptor mediated fast EPSC is generallythe dominant component by far at most glutamatergic synapses, andactivation of AMPA receptors is usually a prerequisite for NMDAreceptors activation.

AMPA receptors are expressed throughout the central nervous system.These receptors are found in high concentrations in the superficiallayers of neocortex, in each of the major synaptic zones of hippocampus,and in the striatal complex, as reported by Monaghan et al., in BrainResearch 324:160-164 (1984). Studies in animals and humans indicate thatthese structures organize complex perceptual-motor processes and providethe substrates for higher-order behaviors. Thus, AMPA receptors mediatetransmission in those brain networks responsible for a host of cognitiveactivities. In addition, AMPA receptors are expressed in brain regionsthat regulate the inspiratory drive responsible for control of breathing(Paarmann et al, Journal of Neurochemistry, 74: 1335-1345 (2000).

For the reasons set forth above, drugs that modulate and thereby enhancethe functioning of AMPA receptors could have significant benefits forintellectual performance as well as reversal of respiratory depressioninduced by pharmacological agents such as opioids and opiates, or othermeans. Such drugs should also facilitate memory encoding. Experimentalstudies, such as those reported by Arai and Lynch, Brain Research598:173-184 (1992), indicate that increasing the size of AMPAreceptor-mediated synaptic response(s) enhances the induction oflong-term potentiation (LTP). LTP is a stable increase in the strengthof synaptic contacts that follows repetitive physiological activity of atype known to occur in the brain during learning.

Compounds that enhance the functioning of the AMPA subtype of glutamatereceptors facilitate the induction of LTP and the acquisition of learnedtasks as measured by a number of paradigms. See, for example, Granger etal., Synapse 15:326-329 (1993); Staubli et al., PNAS 91:777-781 (1994);Arai et al., Brain Res. 638:343-346 (1994); Staubli et al., PNAS91:11158-11162 (1994); Shors et al., Neurosci. Let. 186:153-156 (1995);Larson et al., J. Neurosci. 15:8023-8030 (1995); Granger et al., Synapse22:332-337 (1996); Arai et al., JPET 278:627-638 (1996); Lynch et al.,Internat. Clin. Psychopharm. 11:13-19 (1996); Lynch et al., Exp.Neurology 145:89-92 (1997); Ingvar et al., Exp. Neurology 146:553-559(1997); Hampson, et al., J. Neurosci. 18:2748-2763 (1998); Porrino etal., PLoS Biol 3(9): 1-14 (2006) and Lynch and Rogers, U.S. Pat. No.5,747,492. There is a considerable body of evidence showing that LTP isthe substrate of memory. For example, compounds that block LTP interferewith memory formation in animals, and certain drugs that disruptlearning in humans antagonize the stabilization of LTP, as reported bydel Cerro and Lynch, Neuroscience 49: 1-6 (1992). Learning a simple taskinduces LTP in hippocampus that occludes LTP generated by high frequencystimulation (Whitlock et al., Science 313:1093-1097 (2006)) and amechanism that maintains LTP sustains spatial memory (Pastalkova, etal., Science 313:1141-1144 (2006)). Of significant importance to thefield of learning is the finding that in vivo treatments with a positiveAMPA-type glutamate receptor modulator restores stabilization of basaldendritic LTP in middle-aged animals (Rex, et al., J. Neurophysiol.96:677-685 (2006)).

Drugs that enhance the functioning of the AMPA receptor can effectivelyreverse opioid- and barbiturate-induced respiratory depression withoutreversing the analgesic response (Ren et al, American Journal ofRespiratory and Critical Care Medicine, 174: 1384-1391 (2006). Thereforethese drugs may be useful in preventing or reversing opioid-inducedrespiratory depression and for alleviating other forms of respiratorydepression including sedative use and sleep apnea. Excitatory synaptictransmission provides a major pathway by which neurotrophic factors areincreased within specific brain regions. As such, potentiation of AMPAreceptor function by modulators has been found to increase levels ofneurotrophins, particularly brain derived neurotrophic factor, or BDNF.See, for example, Lauterborn, et al., J. Neurosci. 20:8-21 (2000); Gall,et al., U.S. Pat. No. 6,030,968; Lauterborn, et al., JPET 307:297-305(2003); and Mackowiak, et al., Neuropharmacology 43:1-10 (2002). Otherstudies have linked BDNF levels to a number of neurological disorders,such as Parkinson's disease, Attention Deficit Hyperactivity Disorder(ADHD), autism, Fragile-X Syndrome, and Rett Syndrome (RTT). See, forexample, O'Neill, et al., Eur. J. Pharmacol. 486:163-174 (2004); Kent,et al., Mol. Psychiatry 10:939-943 (2005); Riikonen, et al., J. ChildNeurol. 18:693-697 (2003) and Chang, et al., Neuron 49:341-348 (2006).Thus, AMPA receptor potentiators may be useful for the treatment ofthese, as well as other, neurological diseases that are the result of aglutamatergic imbalance or a deficit in neurotrophic factors.

A prototype for a compound that selectively facilitates the AMPAreceptor has been described by Ito et al., J. Physiol. 424:533-543(1990). These authors found that the nootropic drug aniracetam(N-anisoyl-2-pyrrolidinone) increases currents mediated by brain AMPAreceptors expressed in Xenopus oocytes without affecting responses byy-aminobutyric acid (GABA), kainic acid (KA), or NMDA receptors.Infusion of aniracetam into slices of hippocampus was also shown tosubstantially increase the size of fast synaptic potentials withoutaltering resting membrane properties. It has since been confirmed thataniracetam enhances synaptic responses at several sites in hippocampus,and that it has no effect on NMDA-receptor mediated potentials (Staubliet al., Psychobiology 18:377-381 (1990) and Xiao et al., Hippocampus1:373-380 (1991)).

Aniracetam has been found to have an extremely rapid onset and washout,and can be applied repeatedly with no apparent lasting effects, whichare desirable features for behaviorally-relevant drugs. Aniracetam doespresent several disadvantages, however. The peripheral administration ofaniracetam is not likely to influence brain receptors. The drug worksonly at high concentrations (approx. 1000 μM), and about 80% of the drugis converted to anisoyl-GABA following peripheral administration inhumans (Guenzi and Zanetti, J. Chromatogr. 530:397-406 (1990)). Themetabolite, anisoyl-GABA, has been found to have less activity thananiracetam. In addition to these issues, aniracetam has putative effectson a plethora of other neurotransmitter and enzymatic targets in thebrain, which makes uncertain the mechanism of any claimed therapeuticdrug effect. See, for example, Himori, et al., Pharmacology Biochemistryand Behavior 47:219-225 (1994); Pizzi et al., J. Neurochem. 61:683-689(1993); Nakamura and Shirane, Eur. J. Pharmacol. 380: 81-89 (1999);Spignoli and Pepeu, Pharmacol. Biochem. Behav. 27:491-495 (1987); Halland Von Voigtlander, Neuropharmacology 26:1573-1579(1987); and Yoshimotoet al., J. Pharmacobiodyn. 10:730-735(1987).

A class of AMPA receptor-enhancing compounds that does not display thelow potency and inherent instability characteristic of aniracetam hasbeen described (Lynch and Rogers, U.S. Pat. No. 5,747,492). Thesecompounds, termed “Ampakines”^(R), can be substituted benzamides whichinclude, for example, 6-(piperidin-1-ylcarbonyl)quinoxaline (CX516;Ampalex^(R)). Typically, they are chemically more stable than aniracetamand show improved bioavailability. CX516 is active in animal tests usedto detect efficacious drugs for the treatment of memory disorders,schizophrenia, and depression. In three separate clinical trials, CX516showed evidence for efficacy in improving various forms of human memory(Lynch et al., Internat. Clin. Psychopharm. 11:13-19 (1996); Lynch etal., Exp. Neurology 145:89-92 (1997); Ingvar et al., Exp. Neurology146:553-559 (1997)).

Another class of Ampakines, benzoxazines, has been discovered to havevery high activity in in vitro and in vivo models for assessing theprobability of producing cognition enhancement (Rogers and Lynch; U.S.Pat. No. 5,736,543). The substituted benzoxazines are rigid benzamideanalogues with different receptor modulating properties from theflexible benzamide, CX516.

Certain substituted 2.1.3 benzoxadiazole compounds have been found to besignificantly and surprisingly more potent in animal models of attentiondeficit hyperactivity disorder (ADHD), schizophrenia and cognition thanpreviously disclosed compounds in US 2002/0055508 and US 2002/0099050.This new and novel class of bicyclic amides (A), described in greaterdetail herein, display significant activity for enhancing AMPA mediatedglutamateric synaptic responses.

SUMMARY OF THE INVENTION

The present invention therefore, includes, in one aspect, a compound asshown by structure A and other structures and described in Section H ofthe Detailed Description, which follows. Administration of compounds ofthis class has been found to enhance AMPA mediated glutamatergicsynaptic responses and significantly improve the behavior of rodents inthe d-amphetamine stimulated locomotion assay. This behavioral assay hasproven useful in assessing the efficacy of neuroleptic drugs for thetreatment of schizophrenia and ADHD. The compounds are significantly andsurprisingly more potent than previously described compounds inincreasing glutamatergic synaptic responses in vivo. This activitytranslates into pharmaceutical compounds and corresponding methods ofuse, including treatment methods, which utilize significantly lowerconcentrations of the present compounds compared to prior artcompositions. In addition, compounds within the present inventiondemonstrate improved pharmacokinetic properties compared with previouslydescribed compounds and have good oral bioavailability.

The ability of the compounds of the invention to increase AMPAreceptor-mediated responses makes the compounds useful for a variety ofpurposes. These include facilitating the learning of behaviors dependentupon glutamate receptors, treating conditions in which AMPA receptors,or synapses utilizing these receptors, are reduced in numbers orefficiency, and enhancing excitatory synaptic activity in order torestore an imbalance between brain sub-regions or increase the levels ofneurotrophic factors.

In another aspect, the invention includes a method for the treatment ofa mammalian subject suffering from a hypoglutamatergic condition, orfrom a deficiency in the number or strength of excitatory synapses, orin the number of AMPA receptors, such that memory or other cognitivefunctions are impaired. Such conditions may also cause acortical/striatal imbalance, leading to schizophrenia orschizophreniform behavior.

In another aspect, the invention includes a method for reducing orinhibiting respiratory depression in a subject having respiratorydepression, comprising administering to the subject an amount of acompound of the invention, the amount being sufficient to reduce orinhibit respiratory depression. In one embodiment of the invention, thesubject is a human. In another embodiment, the subject is a mammal. Alsoclaimed is a method for reducing or inhibiting respiratory depressioncomprising administering to the subject an amount of a compound of theinvention in combination with an opioid analgesic; examples of suchopiates include but are not limited to, alfentanil and fentanyl.

In another aspect, the invention includes a method for reducing orinhibiting breathing-related sleep disorders or sleep apnea in a subjecthaving sleep apnea, comprising administering to the subject an amount ofa compound of the invention, the amount being sufficient to reduce orinhibit the breathing related sleep disorder.

According to the methods, such a subject is treated with an effectiveamount of a compound as shown by structure I, and described in SectionII of the Detailed Description, following, in a pharmaceuticallyacceptable carrier. These and other objects and features of theinvention will become more fully apparent when the following detaileddescription of the invention is read in conjunction with theaccompanying drawings.

DETAILED DESCRIPTION OF THE INVENTION

I. Definitions

The terms below have the following meanings unless indicated otherwise.Other terms that are used to describe the present invention have thesame definitions as those terms are generally used by those skilled inthe art.

The term “alkyl” is used herein to refer to a fully saturated monovalentradical containing carbon and hydrogen, and which may be a straightchain, branched or cyclic. Examples of alkyl groups are methyl, ethyl,n-butyl, n-heptyl, isopropyl, 2-methylpropyl.

The term “cycloalkyl” is used herein to refer to a fully saturatedmonovalent radical containing up to 8 carbons and hydrogen in a ring.Examples of cycloalkyl groups are cyclopropyl, cyclobutyl, cyclopentyl,cyclohexyl and cycloheptyl.

The term “bicycloalkyl” is used herein to refer to a fully saturatedmonovalent radical containing up to 10 carbons and hydrogen in abicyclic ring. Examples of bicycloalkyl groups are bicyclo[2.2.2]octyl,bicyclo[2.2.1]heptyl and bicyclo[2.2.3]nonyl and bicylo[3.2.1]octyl.

The term “azabicycloalkyl” is used herein to refer to a fully saturatedmonovalent radical containing up to 10 carbons and hydrogen and 1nitrogen atom in a bicyclic ring. Examples of azabicycloalkyl groups ainclude 1-azabicyclo[2.2.2]octyl, 2-azabicyclo[2.2.2]octyl,1-azabicyclo[2.2.1]heptyl, 2-azabicyclo[2.2.1]heptyl and1-azabicylo[3.2.1]octyl.

The term “alkenyl” is used herein to refer to a monovalent radicalcontaining carbon and hydrogen that contains one or two sites ofun-saturation, and which may be a straight chain, branched or cyclic.Examples of alkenyl groups are ethenyl, n-butenyl, n-heptenyl,isopropenyl, cyclopentenyl, cyclopentenylethyl and cyclohexenyl.“Alkynyl” refers to a monovalent radical containing carbon and hydrogenas described above which contains at least one triple bond.

The term “substituted alkyl” refers to alkyl as just described includingone or more functional groups such as lower alkyl containing 1-6 carbonatoms, aryl, substituted aryl, acyl, halogen (i.e., alkyl halos, e.g.,CF₃), amido, thioamido cyano, nitro, alkynyl, azido, hydroxy, alkoxy,alkoxyalkyl, amino, alkyl and dialkyl-amino, acylamino, acyloxy,aryloxy, aryloxyalkyl, carboxyalkyl, carboxamido, thio, thioethers, bothsaturated and unsaturated cyclic hydrocarbons, heterocycles and thelike.

The term “aryl” refers to a substituted or unsubstituted monovalentaromatic radical having a single ring (e.g., phenyl) or multiplecondensed rings (e.g., naphthyl). Other examples include heterocyclicaromatic ring groups having one or more nitrogen, oxygen, or sulfuratoms in the ring, such as oxazolyl, isoxazolyl, pyrazolyl, thiazolyl,thiadiazolyl, tetrazolyl, pyridazinyl, pyrimidyl, benzofuryl,benzothienyl, benzimidazolyl, benzoxazolyl, benzothiazolyl, quinolyl,isoquinolyl, imidazolyl, furyl, pyrrolyl, pyridyl, thienyl and indolyl.

The term “substituted” as used in the term “substituted aryl,substituted aromatic, substituted heteroaryl, or substitutedheteroaromatic” herein signifies that one or more substituents may bepresent, said substituents being selected from atoms and groups, whichwhen present do not prevent the compound from functioning as apotentiator of AMPA receptor function. Examples of substituents that maybe present in a substituted aromatic or heteroaromatic group include,but are not limited to, groups such as (C₁-C₇) alkyl, (C₁-C₇) acyl,aryl, heteroaryl, substituted aryl and heteroaryl, halogen, cyano,nitro, amido (optionally substituted with one or two C₁-C₇ alkylgroups), thioamido (optionally substituted with one or two C₁-C₇ alkylgroups), azido, alkynyl, (C₁-C₇) alkylhalos (e.g., CF₃), hydroxy,(C₁-C₇) alkoxy, (C₂-C₈) alkoxyalkyl, amino, (C₁-C₇) alkyl and dialkylamino, (C₁-C₇) acylamino, (C₁-C₇) acyloxy, aryloxy, (C₁-C₇)aryloxyalkyl, (C₁-C₇) carboxyalkyl, carboxamido, thio, (C₁-C₇)thioethers, both saturated and unsaturated (C₃-C₈) cyclic hydrocarbons,(C₃-C₈) heterocycles and the like. It is noted that each of thesubstituents disclosed herein may themselves be substituted.

“Heterocycle” or “heterocyclic” refers to a carbocylic ring wherein oneor more carbon atoms have been replaced with one or more heteroatomssuch as nitrogen, oxygen or sulfur.

Examples of heterocycles include, but are not limited to, piperidine,pyrrolidine, morpholine, thiomorpholine, piperazine, tetrahydrofuran,tetrahydropyran, 2-pyrrolidinone, δ-valerolactam, δ-valerolactone and2-ketopiperazine.

The term “substituted heterocycle” refers to a heterocycle as justdescribed which contains or is substituted with one or more functionalgroups (as otherwise described herein) such as lower alkyl, acyl, aryl,cyano, halogen, amido, thioamido, azido, hydroxy, alkoxy, alkoxyalkyl,amino, alkyl and dialkyl-amino, acylamino, acyloxy, aryloxy,aryloxyalkyl, carboxyalkyl, carboxamido, thio, thioethers, bothsaturated and unsaturated cyclic hydrocarbons, heterocycles and thelike, as otherwise described herein.

The term “compound” is used herein to refer to any specific chemicalcompound disclosed herein. Within its use in context, the term generallyrefers to a single stable compound, but in certain instances may alsorefer to stereoisomers and/or optical isomers (including enantiopurecompounds, enantiomerically enriched compounds and racemic mixtures) ofdisclosed compounds.

The term “effective amount” refers to the amount of a selected compoundof formula I that is used within the context of its intended use toeffect an intended result, for example, to enhance glutamatergicsynaptic response by increasing AMPA receptor activity. The preciseamount used will vary depending upon the particular compound selectedand its intended use, the age and weight of the subject, route ofadministration, and so forth, but may be easily determined by routineexperimentation. In the case of the treatment of a condition or diseasestate, an effective amount is that amount which is used to effectivelytreat the particular condition or disease state.

The term “pharmaceutically acceptable carrier” refers to a carrier orexcipient which is not unacceptably toxic to the subject to which it isadministered. Pharmaceutically acceptable excipients are described atlength by E. W. Martin, in “Remington's Pharmaceutical Sciences.”

A “pharmaceutically acceptable salt” of an amine compound, such as thosecontemplated in the current invention, is an ammonium salt having ascounter ion an inorganic anion such as chloride, bromide, iodide,sulfate, sulfite, nitrate, nitrite, phosphate, and the like, or anorganic anion such as acetate, malonate, pyruvate, propionate, fumarate,cinnamate, tosylate, and the like.

The term “patient” or “subject” is used throughout the specification todescribe an animal, generally a mammalian animal, including a human, towhom treatment or use with the compounds or compositions according tothe present invention is provided. For treatment or use with/or of thoseconditions or disease states which are specific for a specific animal(especially, for example, a human subject or patient), the term patientor subject refers to that particular animal.

The term “sensory motor problems” is used to describe a problem whicharises in a patient or subject from the inability to integrate externalinformation derived from the five known senses in such a way as todirect appropriate physical responses involving movement and action.

The term “cognitive task” or “cognitive function” is used to describe anendeavor or process by a patient or subject that involves thought orknowing. The diverse functions of the association cortices of theparietal, temporal and frontal lobes, which account for approximately75% of all human brain tissue, are responsible for much of theinformation processing that goes on between sensory input and motoroutput. The diverse functions of the association cortices are oftenreferred to as cognition, which literally means the process by which wecome to know the world. Selectively attending to a particular stimulus,recognizing and identifying these relevant stimulus features andplanning and experiencing the response are some of the processes orabilities mediated by the human brain which are related to cognition.

The term “brain network” is used to describe different anatomicalregions of the brain that communicate with one another via the synapticactivity of neuronal cells.

The term “AMPA receptor” refers to an aggregate of proteins found insome membranes, which allows positive ions to cross the membrane inresponse to the binding of glutamate or AMPA(DL-α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid), but not NMDA.

The term “excitatory synapse” is used to describe a cell-cell junctionat which release of a chemical messenger by one cell causesdepolarization of the external membrane of the other cell. An excitatorysynapse describes a postsynaptic neuron which has a reversal potentialthat is more positive than the threshold potential and consequently, insuch a synapse, a neurotransmitter increases the probability that anexcitatory post synaptic potential will result (a neuron will fireproducing an action potential). Reversal potentials and thresholdpotentials determine postsynaptic excitation and inhibition. If thereversal potential for a post synaptic potential (“PSP”) is morepositive than the action potential threshold, the effect of atransmitter is excitatory and produces an excitatory post synapticpotential (“EPSP”) and the firing of an action potential by the neuron.If the reversal potential for a post synaptic potential is more negativethan the action potential threshold, the transmitter is inhibitory andmay generate inhibitory post synaptic potentials (IPSP), thus reducingthe likelihood that a synapse will fire an action potential. The generalrule for postsynaptic action is: if the reversal potential is morepositive than threshold, excitation results; inhibition occurs if thereversal potential is more negative than threshold. See, for example,Chapter 7, NEUROSCIENCE, edited by Dale Purves, Sinauer Associates,Inc., Sunderland, Mass. 1997.

The term “motor task” is used to describe an endeavor taken by a patientor subject that involves movement or action.

The term “perceptual task” is used to describe an act by a patient orsubject of devoting attention to sensory inputs.

The term “synaptic response” is used to describe biophysical reactionsin one cell as a consequence of the release of chemical messengers byanother cell with which it is in close contact.

The term “hypoglutamatergic condition” is used to describe a state orcondition in which transmission mediated by glutamate (or relatedexcitatory amino acids) is reduced to below normal levels. Transmissionconsists of the release of glutamate, binding to post synapticreceptors, and the opening of channels integral to those receptors. Theend point of the hypoglutamatergic condition is reduced excitatory postsynaptic current. It can arise from any of the three above noted phasesof transmission. Conditions or disease states which are consideredhypoglutamatergic conditions and which can be treated using thecompounds, compositions and methods according to the present inventioninclude, for example, loss of memory, dementia, depression, attentiondisorders, sexual dysfunction, movement disorders, including Parkinson'sdisease, schizophrenia or schizophreniform behavior, memory and learningdisorders, including those disorders which result from aging, trauma,stroke and neurodegenerative disorders, such as those associated withdrug-induced states, neurotoxic agents, Alzheimer's disease and aging,respiratory depression and sleep apnea. These conditions are readilyrecognized and diagnosed by those of ordinary skill in the art.

The term “cortico-striatal imbalance” is used to describe a state inwhich the balance of neuronal activities in the interconnected cortexand underlying striatal complex deviates from that normally found.‘Activity’ can be assessed by electrical recording or molecularbiological techniques. Imbalance can be established by applying thesemeasures to the two structures or by functional (behavioral orphysiological) criteria.

The term “affective disorder” or “mood disorder” describes the conditionwhen sadness or elation is overly intense and continues beyond theexpected impact of a stressful life event, or arises endogenously. Asused herein, the term “effective disorder” embraces all types of mooddisorders as described in, for example, Diagnostic and StatisticalManual of Mental Disorders, Fourth Edition (DSM IV), pages 317-391.

The term “schizophrenia” is used to describe a condition which is acommon type of psychosis, characterized by a disorder in the thinkingprocesses, such as delusions and hallucinations, and extensivewithdrawal of the individual's interest from other people and theoutside world, and the investment of it in his or her own. Schizophreniais now considered a group of mental disorders rather than a singleentity, and distinction is made between reactive and processschizophrenias. As used herein, the term schizophrenia or“schizophreniform” embraces all types of schizophrenia, includingambulatory schizophrenia, catatonic schizophrenia, hebephrenicschizophrenia, latent schizophrenia, process schizophrenia,pseudoneurotic schizophrenia, reactive schizophrenia, simpleschizophrenia, and related psychotic disorders which are similar toschizophrenia, but which are not necessarily diagnosed as schizophreniaper se. Schizophrenia and other psychotic disorders may be diagnosedusing guidelines established in, for example, Diagnostic and StatisticalManual of Mental Disorders, Fourth Edition (DSM IV) Sections 293.81,293.82, 295.10, 295.20, 295.30, 295.40, 295.60, 295.70, 295.90, 297.1,297.3, 298.8.

The term “brain function” is used to describe the combined tasks ofperceiving, integrating, filtering and responding to external stimuliand internal motivational processes.

The term “impaired” is used to describe a function working at a levelthat is less than normal. Impaired functions can be significantlyimpacted such that a function is barely being carried out, is virtuallynon-existent or is working in a fashion that is significantly less thannormal. Impaired functions may also be sub-optimal. The impairment offunction will vary in severity from patient to patient and the conditionto be treated.

The term “respiratory depression” as used herein refers to a variety ofconditions characterized by reduced respiratory frequency andinspiratory drive to cranial and spinal motor neurons. Specifically,respiratory depression refers to conditions where the medullary neuralnetwork associated with respiratory rhythm generating activity does notrespond to accumulating levels of PCO₂ (or decreasing levels of PO₂) inthe blood and subsequently under stimulates motorneurons controllinglung musculature.

The term “sleep apnea” as used herein refers to breathing-related sleepdisorders of which there are two types: central and obstructive. CentralSleep Apnea is defined as a neurological condition causing cessation ofall respiratory effort during sleep, usually with decreases in bloodoxygen saturation, if the brainstem center controlling breathing shutsdown there's no respiratory effort and no breathing. The person isaroused from sleep by an automatic breathing reflex, so may end upgetting very little sleep at all. Obstructive sleep apnea ischaracterized by repetitive pauses in breathing during sleep due to theobstruction and/or collapse of the upper airway and followed by anawakening to breathe. Respiratory effort continues during the episodesof apnea.

The term “pro-drug” as used herein refers to a metabolically labilederivative that is pharmacologically inactive in the parent form butthat is rapidly metabolized in human or animal plasma to apharmacologically active form. Examples of pro-drugs as used hereininclude but in no way are limited to ester derivatives of hydroxylcontaining moieties, such esters include but are not limited to thoseformed from substituted or un-substituted natural or un-natural aminoacids.

II. Compounds of the Present Invention

The present invention is directed to compounds having the property ofenhancing AMPA receptor function. These include compounds having thestructure A, below:

wherein:

-   W is oxygen, sulfur or CH═CH;-   X, Y and Z are independently selected from the group consisting of    —N, or —CR,    wherein:-   R is H, —Br, —Cl, —F, —CN, —NO₂, —OR¹, —SR¹, —NR¹ ₂, —C₁-C₆ branched    or un-branched alkyl, which may be un-substituted or substituted,    wherein:-   R¹ is H, —C₁-C₆ branched or un-branched alkyl which, may be    un-substituted or substituted,-   n=0-5 (such that from 0 to 5 methylene groups are present)-   m=0-5 (such that from 0 to 5 methylene groups are present)-   p=0-5 (such that from 0 to 5 methylene groups are present)-   R² and R³ are each independently selected from H, a halogen    (preferably F), —CN, —NO₂, —OR¹, —SR¹, —NR¹ ₂, CF₃, OH, C═O, a    —C₁-C₆ branched or un-branched alkyl, which may be un-substituted or    substituted, a —C₂-C₆ branched or un-branched alkenyl, which may be    un-substituted or substituted, a —C₂-C₆ branched or un-branched    alkynyl, which may be un-substituted or substituted, a —C₃-C₇    cycloalkyl which may be un-substituted or substituted, an aryl which    may be un-substituted or substituted, a heterocycle which may be    un-substituted or substituted, a carboxyalkyl which may be    un-substituted or substituted, a carboxyaryl which may be    un-substituted or substituted, a carboxyheteroaryl which may be    un-substituted or substituted, a sulfonylalkyl which may be    un-substituted or substituted, a sulfonylaryl which may be    un-substituted or substituted or a sulfonylheteroaryl which may be    un-substituted or substituted,-   E and F are each independently selected from CH₂m, CR²R³, A, CH₂A,    CR²═CR³ or are absent, with the proviso that E and F are not both    absent;-   G is CR²R³, A, CH₂A, CR²═CR³, CH₂C═O, CH₂CR²R³, or absent,-   A is O, S, SO, SO₂, C═O or CR²R³;    or a pharmaceutically acceptable salt, solvate, or polymorph    thereof.

The present invention is directed, in another aspect, to compoundshaving the property of enhancing AMPA receptor function. These includecompounds having the structure I, below:

wherein:

-   W is oxygen, sulfur or CH═CH;-   X, Y and Z are independently selected from the group consisting of    —N, or —CR,    wherein:-   R is H, —Br, —Cl, —F, —CN, —NO₂, —OR¹, —SR¹, —NR¹ ₂, —C₁-C₆ branched    or un-branched alkyl, which may be un-substituted or substituted,    wherein:-   R¹ is H, —C₁-C₆ branched or un-branched alkyl which, may be    un-substituted or substituted,-   n=0-5 (such that from 0 to 5 methylene groups are present)-   m=0-5 (such that from 0 to 5 methylene groups are present)-   p=0-5 (such that from 0 to 5 methylene groups are present)-   R² and R³ are independently selected from H, a halogen (preferably    F), —CN, —NO₂, —OR¹, —SR¹, —NR¹ ₂, CF₃, OH, C═O, a —C₁-C₆ branched    or un-branched alkyl, which may be un-substituted or substituted, a    —C₂-C₆ branched or un-branched alkenyl, which may be un-substituted    or substituted, a —C₂-C₆ branched or un-branched alkynyl, which may    be un-substituted or substituted, a —C₃-C₇ cycloalkyl which may be    un-substituted or substituted, an aryl which may be un-substituted    or substituted, a heterocycle which may be un-substituted or    substituted, a carboxyalkyl which may be un-substituted or    substituted, a carboxyaryl which may be un-substituted or    substituted, a carboxyheteroaryl which may be un-substituted or    substituted, a sulfonylalkyl which may be un-substituted or    substituted, a sulfonylaryl which may be un-substituted or    substituted or a sulfonylheteroaryl which may be un-substituted or    substituted, or a pharmaceutically acceptable salt, solvate, or    polymorph thereof.

The azabicyclic ring may also be an unsaturated azabicyclic ring asrepresented by structure II:

wherein:

-   W, X, Y and Z are as defined for structure I, above-   n=0-5 (such that from 0 to 5 methylene groups are present)-   m=0-5 (such that from 0 to 5 methylene groups are present)-   p=0-4 (such that from 0 to 4 methylene groups are present)-   and R² and R³ are as defined for structure I, or a pharmaceutically    acceptable salt, solvate, or polymorph thereof.

The azabicyclic ring may also be represented by structure III:

wherein:

-   W, X, Y and Z are as defined for structure I, above-   A is O, S, SO, SO₂, C═O or CR²R³;-   n=0-5 (such that from 0 to 5 methylene groups are present)-   m=1-5 (such that from 0 to 5 methylene groups are present)-   p=0-5 (such that from 0 to 5 methylene groups are present)-   and R² and R³ are as defined for structure I, or a pharmaceutically    acceptable salt, solvate, or polymorph thereof.

In a further aspect of the present invention, the azabicyclic ringincludes compounds of structure IV:

wherein:

-   W, X, Y and Z are as defined for structure I, above-   A is O, S, SO, SO₂, C═O or CR²R³;-   n=1-5 (such that from 1 to 5 methylene groups are present)-   m=1-5 (such that from 1 to 5 methylene groups are present)-   p=0-5 (such that from 0 to 5 methylene groups are present)-   and R² and R³ are as defined for structure I, or a pharmaceutically    acceptable salt, solvate, or polymorph thereof.

In a further aspect, the present invention provides compounds ofFormulas A and I-IV selected from:

-   8-Azabicyclo[3.2.1]oct-8-yl([2,1,3]-benzoxadiazol-5-yl)methanone-   8-([2,1,3]-Benzoxadiazol-5-ylcarbonyl)-8-azabicyclo[3.2.1]octan-3-one-   [2,1,3]-Benzoxadiazol-5-yl(3,3-difluoro-8-azabicyclo[3.2.1]oct-8-yl)methanone-   [2,1,3]-Benzoxadiazol-5-yl(3-fluoro-8-azabicyclo[3.2.1]oct-2-en-8-yl)methanone-   endo-[2,1,3]-Benzoxadiazol-5-yl(3-hydroxy-8-azabicyclo[3.2.1]oct-8-yl)methanone-   exo-[2,1,3]-Benzoxadiazol-5-yl(3-hydroxy-8-azabicyclo[3.2.1]oct-8-yl)methanone-   2-Azabicyclo[2.2.1]hept-2-yl([2,1,3]-benzoxadiazol-5-yl)methanone-   1-Azabicyclo[2.2.1]hept-1-yl([2,1,3]-benzoxadiazol-5-yl)methanone-   2-Azabicyclo[2.2.2]oct-2-yl([2,1,3]-benzoxadiazol-5-yl)methanone-   [2,1,3]-Benzoxadiazol-5-yl(2-oxa-5azabicyclo[2.2.1]hept-5-yl)methanone-   2-Azabicyclo[2.2.1]hept-5-en-2-yl([2,1,3]-benzoxadiazol-5-yl)methanone-   [2,1,3]-Benzoxadiazol-5-yl(5,6-dichloro-2-azabicyclo[2.2.1]hept-2-yl)methanone-   R-2-Azabicyclo[2.2.1]hept-5-en-2-yl([2,1,3]-benzoxadiazol-5-yl)methanone-   S-2-Azabicyclo[2.2.1]hept-5-en-2-yl([2,1,3]-benzoxadiazol-5-yl)methanone    III. Synthesis

The synthesis of the compounds of the invention, are preferably carriedout by the following Scheme. Alternative syntheses by analogy relying onmethodology that exists in the art also may be used. Each compound maybe made using the described synthesis by following the proposedchemistry as presented herein or by making minor modifications in thesynthetic chemistry relying on well known methods available in the art.The approach to synthesis is rather facile and may be readily modifiedwithin the scope of the present teachings. Acid chloride 4 issynthesized starting with 4-amino-3-nitrobenzoic acid 1 by firstlyoxidizing using bleach to give intermediate 2 and then reducing withtriethyl phosphite (P(OEt)₃) to give benzofurazan carboxylic acid 3. Thecarboxylic acid 3 was transformed to the acid chloride 4 by refluxingwith thionyl chloride and a catalytic amount of DMF in toluene. Thecarboxylic acid 3 can be transformed into bicyclic amides 5 by reactionwith aminobicycles using standard coupling conditions like CDI, EDCI,HBTU in a suitable solvent. Alternatively, acid chloride 4 can betransformed into bicyclic amides 5 under standard coupling conditionswith bicyclic amines in the presence of a base for example triethylamineor aqueous sodium hydroxide, among others in a suitable solvent, forexample dichloromethane. The benzothiadiazole amides 6 are prepared fromthe commercially available benzothiadiazole acid chloride under standardcoupling conditions in the presence of a base for example triethylamineor aqueous sodium hydroxide in a suitable solvent for exampledichloromethane. Quinoxaline-6-carboxylic acid chloride is prepared bycondensation of commercially available 3,4-diaminobenzoic acid withglyoxal followed by refluxing with thionyl chloride and a catalyticamount of DMF in toluene using standard procedures. Reaction ofquinoxaline-6-carboxylic acid chloride with bicyclic amines gave thedesired quinoxaline bicyclic amides (7). The alternative azabicycles asrepresented by structures II-IV are made in a similar fashion using theappropriate azabicycle to couple with the carboxyxlic acid chloride 4.

IV. Method of Treatment

According to one aspect of the invention, a method is provided fortreating a mammalian subject suffering from a hypoglutamatergiccondition, or from deficiencies in the number or strength of excitatorysynapses or in the number of AMPA receptors. In such a subject, memoryor other cognitive functions may be impaired, or cortical/striatalimbalance may occur, leading to loss of memory, dementia, depression,attention disorders, sexual dysfunction, movement disorders,schizophrenia or schizophreniform behavior. Memory disorders andlearning disorders, which are treatable according to the presentinvention include those disorders that result from aging, trauma, strokeand neurodegenerative disorders. Examples of neurodegenerative disordersinclude, but are not limited to, those associated with drug-inducedstates, neurotoxic agents, Alzheimer's disease, and aging. Theseconditions are readily recognized and diagnosed by those of ordinaryskill in the art and treated by administering to the patient aneffective amount of one or more compounds according to the presentinvention.

In another aspect, the invention provides a method for reducing orinhibiting respiratory depression in a subject having such a condition,comprising administering to the subject an amount of a compound of theinvention, the amount being sufficient to reduce or inhibit respiratorydepression. In a further aspect of the invention, a method is providedfor reducing or inhibiting respiratory depression comprisingadministering to the subject an amount of a compound of the invention incombination with an opiate; examples of such opiates include but are notlimited to, alfentanil and fentanyl.

In a further aspect, the invention provides a method for reducing orinhibiting breathing-related sleep disorders or sleep apnea in a subjecthaving sleep apnea, comprising administering to the subject an amount ofa compound of the invention, the amount being sufficient to reduce orinhibit the breathing related sleep disorder.

In the present invention, the method of treatment comprisesadministering to the subject in need of treatment, in a pharmaceuticallyacceptable carrier, an effective amount of a compound having the FormulaA below:

wherein:

-   W is oxygen, sulfur or CH═CH;-   X, Y and Z are independently selected from the group consisting of    —N, or —CR,    wherein:-   R is H, —Br, —Cl, —F, —CN, —NO₂, —OR¹, —SR¹, —NR¹ ₂, —C₁-C₆ branched    or un-branched alkyl, which may be un-substituted or substituted,    wherein:-   R¹ is H, —C₁-C₆ branched or un-branched alkyl which, may be    un-substituted or substituted,-   n=0-5 (such that from 0 to 5 methylene groups are present)-   m=0-5 (such that from 0 to 5 methylene groups are present)-   p=0-5 (such that from 0 to 5 methylene groups are present)-   R² and R³ are each independently selected from H, a halogen    (preferably F), —CN, —NO₂, —OR¹, —SR¹, —NR¹ ₂, CF₃, OH, C═O, a    —C₁-C₆ branched or un-branched alkyl, which may be un-substituted or    substituted, a —C₂-C₆ branched or un-branched alkenyl, which may be    un-substituted or substituted, a —C₂-C₆ branched or un-branched    alkynyl, which may be un-substituted or substituted, a —C₃-C₇    cycloalkyl which may be un-substituted or substituted, an aryl which    may be un-substituted or substituted, a heterocycle which may be    un-substituted or substituted, a carboxyalkyl which may be    un-substituted or substituted, a carboxyaryl which may be    un-substituted or substituted, a carboxyheteroaryl which may be    un-substituted or substituted, a sulfonylalkyl which may be    un-substituted or substituted, a sulfonylaryl which may be    un-substituted or substituted or a sulfonylheteroaryl which may be    un-substituted or substituted,-   E and F are each independently selected from CH₂m, CR²R³, A, CH₂A,    CR²═CR³ or are absent, with the proviso that E and F are not both    absent;-   G is CR²R³, A, CH₂A, CR²═CR³, CH₂C═O, CH₂CR²R³, or absent,-   A is O, S, SO, SO₂, C═O or CR²R³;    or a pharmaceutically acceptable salt, solvate, or polymorph    thereof.

In a further aspect of the present invention, the method of treatmentcomprises administering to the subject in need of treatment, in apharmaceutically acceptable carrier, an effective amount of a compoundhaving the Formula I below:

wherein:

-   W is oxygen, sulfur or CH═CH;-   X, Y and Z are independently selected from the group consisting of    —N, or —CR,    wherein:-   R is H, —Br, —Cl, —F, —CN, —NO₂, —OR¹, —SR¹, —NR¹ ₂, —C₁-C₆ branched    or un-branched alkyl, which may be un-substituted or substituted,    wherein:-   R¹ is H, —C₁-C₆ branched or un-branched alkyl which may be    un-substituted or substituted,-   n=0-5 (such that from 0 to 5 methylene groups are present)-   m=0-5 (such that from 0 to 5 methylene groups are present)-   p=0-5 (such that from 0 to 5 methylene groups are present)-   R² and R³ are independently selected from H, a halogen (preferably    F), —CN, —NO₂, —OR¹, —SR¹, —NR¹ ₂, CF₃, OH, C═O, a —C₁-C₆ branched    or un-branched alkyl, which may be un-substituted or substituted, a    —C₂-C₆ branched or un-branched alkenyl, which may be un-substituted    or substituted, a —C₂-C₆ branched or un-branched alkynyl, which may    be un-substituted or substituted, a —C₃-C₇ cycloalkyl which may be    un-substituted or substituted, an aryl which may be un-substituted    or substituted, a heterocycle which may be un-substituted or    substituted, a carboxyalkyl which may be un-substituted or    substituted, a carboxyaryl which may be un-substituted or    substituted, a carboxyheteroaryl which may be un-substituted or    substituted, a sulfonylalkyl which may be un-substituted or    substituted, a sulfonylaryl which may be un-substituted or    substituted or a sulfonylheteroaryl which may be un-substituted or    substituted, or a pharmaceutically acceptable salt, solvate, or    polymorph thereof.

In a further method aspect of the invention azabicyclic compoundsrepresented by structure II are preferred to be used in the methodaspect:

wherein:

-   W, X, Y and Z are as defined for structure I-   n=0-5-   m=0-5-   p=0-4-   and R² and R³ are as defined for structure I, or a pharmaceutically    acceptable salt, solvate, or polymorph thereof.

In yet a further method aspect of the invention, preferred embodimentsinclude compounds represented by structure III:

wherein:

-   W, X, Y and Z are as defined for structure I-   A is O, S, SO, SO₂, C═O or CR²R³;-   n=0-5-   m=1-5-   p=0-5-   and R² and R³ are as defined for structure I, or a pharmaceutically    acceptable salt, solvate, or polymorph thereof.

In yet a further method aspect of the invention, preferred embodimentsinclude compounds represented by structure IV:

wherein:

-   W, X, Y and Z are as defined for structure I-   A is O, S, SO, SO₂, C═O or CR²R³;-   n=1-5-   m=1-5-   p=0-5-   and R² and R³ are as defined for structure I, or a pharmaceutically    acceptable salt, solvate, or polymorph thereof.

Compounds according to the present invention exhibit enhancedbioavailability in most instances due, at least in part, to enhancedpharmacokinetics exhibited by the present compounds. Accordingly, thepresent compounds may be favorably formulated into pharmaceuticalcompositions in a variety of dosage forms, and in particular, oraldosage forms.

As noted above, treatment of a subject according to the method of theinvention is useful for enhancing AMPA receptor activity, and thus maybe used to facilitate the learning of behaviors dependent upon AMPAreceptors, and to treat conditions, such as memory impairment, in whichAMPA receptors, or synapses utilizing these receptors, are reduced innumbers or efficiency. The method is also useful for enhancingexcitatory synaptic activity in order to restore an imbalance betweenbrain sub-regions, which may manifest itself in schizophrenia orschizophreniform behavior, or other behavior as described above. Thecompounds administered in accordance with the method have been found tobe more effective than previously described compounds in enhancing AMPAreceptor activity, as shown in the in vivo tests described below.

V. Biological Activity

A. Enhancement of AMPA Receptor Function In Vivo.

Synaptic responses mediated by AMPA receptors are increased according tothe method of the invention, using the compounds described herein.

The electrophysiological effects of the invention compounds were testedin vivo in anesthetized animals according to the following procedures.Animals are maintained under anesthesia by phenobarbital administeredusing a Hamilton syringe pump. Stimulating and recording electrodes areinserted into the perforant path and dentate gyrus of the hippocampus,respectively. Once electrodes are implanted, a stable baseline of evokedresponses are elicited using single monophasic pulses (100 μs pulseduration) delivered at 3/min to the stimulating electrode. Field EPSPsare monitored until a stable baseline is achieved (about 20-30 min),after which a solution of test compound is injected intraperitoneallyand evoked field potentials are recorded. Evoked potentials wererecorded for approximately 2 h following drug administration or untilthe amplitude of the field EPSP returns to baseline. In the latterinstance, it is common that an iv administration is also carried outwith an appropriate dose of the same test compound. Invention compoundswere assayed in the in vivo electrophysiology assay described above anddata for representative test compounds is shown in column 1 in Table 1.Compounds of the invention are significantly more active in increasingthe amplitude of the field EPSP in the rat dentate gyrus following i.p.dosing than CX516 (1-(quinoxalin-6-ylcarbonyl)piperidine; U.S. Pat. No.5,773,434, US2002/0055508) which gave a 9% increase in amplitude of thefield EPSP at 50 mg/kg i.p.

TABLE 1 ²Inhibition of d- Compound Example ¹In vivo AmphetamineStimulated Number Electrophysiology Locomotion 1 22% 69% 2 16% 40% 3  8%NT 4 25% NT 7  20%³ NT ¹% increase in the amplitude of the field EPSP inthe dentate gyrus of rat @ 10 mpk i.p. ²% Inhibition of d-amphetaminestimulated locomotion in mice @ 18 mpk i.p. ³Dosed i.v. NT = Not testedB. Behavioral Testing: Inhibition of d-Amphetamine Stimulated Locomotion

The ability of the invention compounds to inhibit d-Amphetaminestimulated locomotor activity was assayed according to the followingprocedure. Male CD1 mice, 25-30 gm body o weight, were brought into theexperimental room and allowed at least 30 min of acclamation.

Each mouse was placed into the testing enclosure with an infrared beamarray that automatically monitors the animal's activity. Mice werehabituated in the testing enclosure for 20 min, and then returned totheir home cage. Mice were dosed intraperitoneally with test compound inappropriate vehicle 5 minutes before d-Amphetamine injection (2 mpk).Ten minutes after d-Amphetamine injection, mice were tested forlocomotor activity for a total of 15 minutes. The data was computercollected and expressed as “arbitrary movement units.” All data wereanalyzed by comparing the groups treated with the test compound to thevehicle control group. The data for test compounds is shown in Table 1,column 2. The data shown is the % inhibition of hyperactivity induced byacute administration of 2 mg/kg d-amphetamine in mice. The compoundstested produced a statistically significant inhibition of d-amphetaminestimulated locomotion.

VI. Administration, Dosages, and Formulation

As noted above, the compounds and method of the invention increaseglutamatergic synaptic responses mediated by AMPA receptors, and areuseful for the treatment of hypoglutamatergic conditions. They are alsouseful for treatment of conditions such as impairment of memory or othercognitive functions, brought on by a deficiency in the number orstrength of excitatory synapses, or in the number of AMPA receptors.They may also be used in the treatment of schizophrenia orschizophreniform behavior resulting from a cortical/striatal imbalance,and in facilitation of learning of behaviors dependent upon AMPAreceptors.

In subjects treated with the present compounds, pharmaceuticalcompositions and methods memory or other cognitive functions may beimpaired or cortical/striatal imbalance may occur, leading to loss ofmemory, dementia, depression, attention disorders, sexual dysfunction,movement disorders, schizophrenia or schizophreniform behavior. Memorydisorders and learning disorders, which are treatable according to thepresent invention, include those disorders that result from aging,trauma, stroke and neurodegenerative disorders. Examples ofneurodegenerative disorders include, but are not limited to, thoseassociated with drug-induced states, neurotoxic agents, Alzheimer'sdisease, and aging. These conditions are readily recognized anddiagnosed by those of ordinary skill in the art and treated byadministering to the patient an effective amount of one or morecompounds according to the present invention.

Generally, dosages and routes of administration of the compound will bedetermined according to the size and condition of the subject, accordingto standard pharmaceutical practices. Dose levels employed can varywidely, and can readily be determined by those of skill in the art.Typically, amounts in the milligram up to gram quantities are employed.The composition may be administered to a subject by various routes, e.g.orally, transdermally, perineurally or parenterally, that is, byintravenous, subcutaneous, intraperitoneal, or intramuscular injection,among others, including buccal, rectal and transdermal administration.Subjects contemplated for treatment according to the method of theinvention include humans, companion animals, laboratory animals, and thelike.

Formulations containing the compounds according to the present inventionmay take the form of solid, semi-solid, lyophilized powder, or liquiddosage forms, such as, for example, tablets, capsules, powders,sustained-release formulations, solutions, suspensions, emulsions,suppositories, creams, ointments, lotions, aerosols, patches or thelike, preferably in unit dosage forms suitable for simple administrationof precise dosages.

Pharmaceutical compositions according to the present invention comprisean effective amount of one or more compounds according to the presentinvention and typically include a conventional pharmaceutical carrier orexcipient and may additionally include other medicinal agents, carriers,adjuvants, additives and the like. Preferably, the composition will beabout 0.5 to 75% by weight or more of a compound or compounds of theinvention, with the remainder consisting essentially of suitablepharmaceutical excipients. For oral administration, such excipientsinclude pharmaceutical grades of mannitol, lactose, starch, magnesiumstearate, sodium saccharine, talcum, cellulose, glucose, gelatin,sucrose, magnesium carbonate, and the like. If desired, the compositionmay also contain minor amounts of non-toxic auxiliary substances such aswetting agents, emulsifying agents, or buffers.

Liquid compositions can be prepared by dissolving or dispersing thecompounds (about 0.5% to about 20% by weight or more), and optionalpharmaceutical adjuvants, in a carrier, such as, for example, aqueoussaline, aqueous dextrose, glycerol, or ethanol, to form a solution orsuspension. For use in oral liquid preparation, the composition may beprepared as a solution, suspension, emulsion, or syrup, being suppliedeither in liquid form or a dried form suitable for hydration in water ornormal saline.

When the composition is employed in the form of solid preparations fororal administration, the preparations may be tablets, granules, powders,capsules or the like. In a tablet formulation, the composition istypically formulated with additives, e.g. an excipient such as asaccharide or cellulose preparation, a binder such as starch paste ormethyl cellulose, a filler, a disintegrator, and other additivestypically used in the manufacture of medical preparations.

An injectable composition for parenteral administration will typicallycontain the compound in a suitable i.v. solution, such as sterilephysiological salt solution. The composition may also be formulated as asuspension in a lipid or phospholipid, in a liposomal suspension, or inan aqueous emulsion.

Methods for preparing such dosage forms are known or will be apparent tothose skilled in the art; for example, see Remington's PharmaceuticalSciences (17th Ed., Mack Pub. Co., 1985). The composition to beadministered will contain a quantity of the selected compound in apharmaceutically effective amount for effecting increased AMPA receptorcurrents in a subject.

The following examples illustrate but are not intended in any way tolimit the invention. Unless otherwise stated, all temperatures are givenin degrees Celsius. Unless otherwise stated, all NMR spectra are ¹H NMRspectra and were obtained in deuterochloroform or deuterated DMSO assolvent using tetramethylsilane as an internal standard. All names ofExample compounds conform to IUPAC nomenclature as provided by thecomputer software ChemSketch by ACD Labs.

I. Chemical Methods Intermediate 1 2,1,3-Benzoxadiazole-5-carboxylicacid

In a 3 L reactor fitted with mechanical stirring, reflux condenser,thermometer and nitrogen inlet, KOH (72.46 g) was dissolved in ethanol(250 ml) and water (250 ml). 4-Amino-3-nitrobenzoic acid (100 g) wasadded and the orange suspension was heated to 65-70° C. within 30minutes. The resulting suspension was stirred at the same temperaturefor 45 minutes and cooled to 0° C.±5° C. within 30 minutes. Acommercially available (13% w/w) solution of sodium hypochlorite (448.93g) was added drop wise within 1.5 hours at 0° C.±5° C. The reactionmixture was stirred at the same temperature for 2 hours and controlledby TLC (CHCl₃ 100/acetone 2/acetic acid 1). Water (350 ml) was addedwithin 15 minutes at 0° C.±5° C. to give a fine yellow suspension. Thereaction mixture was then acidified with a 6N HCl solution (239 ml)until 0.5<pH<1 was reached. NaCl (58.44 g) was added and the resultingsuspension was stirred at 0° C.±5° C. for 1.5 hours under nitrogen. Thesolid was collected by filtration, washed with 3×400 ml water and dried(40° C., 30 mbars, 12 hours) to yield 83.6 g (88.8% yield) of2,1,3-benzoxadiazole-5-carboxylic acid N-oxide.

In a 2 L reactor fitted with mechanical stirring, thermometer, additionfunnel, reflux condenser and nitrogen inlet,2,1,3-benzoxadiazole-5-carboxylic acid N-oxide (80 g) was dissolved inabsolute ethanol (800 ml). To this solution triethyl phosphite (114.05g) was added within 10 minutes at 70° C.±2° C. The resulting mixture washeated to reflux (76-78° C.) and maintained for 2 hours. TLC monitoring(CHCl₃ 100/acetone 2/acetic acid 1) showed complete reaction. Thesolvent was removed under vacuum (30 mbars, 40° C.) which yielded ablack oil (180 g). Water (400 ml) was added and the mixture wasextracted with ethyl acetate (400 and 160 ml). The organic phase wasextracted with 850 ml water containing NaOH (9.5<pH<10). The aqueousphase was separated and extracted with ethyl acetate (3×240 ml). Theaqueous phase was acidified (78 ml 6 N HCl) to 1<pH<2 at 5° C.±2° C.which resulted in the crystallization of the yellow product, which wasfiltered off and dried (40° C., 30 mbars, 12 hours) to yield 65.56 g(90% yield) 2,1,3-benzoxadiazole-5-carboxylic acid: mp=160-161° C., ¹HNMR (300 MHz, DMSO) δ 13.8 (s, 1H); 8.57 (s, 1H); 8.56 (d, 1H, J=0.6Hz); 7.87 ppm (d, 1H, J=0.6 Hz).

Intermediate 2 2,1,3-Benzoxadiazole-5-carbonylchloride

In a 500 ml reactor fitted with mechanical stirring, thermometer,addition funnel, reflux condenser and nitrogen inlet,2,1,3-benzoxadiazole-5-carboxylic acid (28 g) was suspended in toluene(245 ml). To this suspension was added thionyl chloride (39.4 g) and DMF(0.35 ml). The resulting mixture was heated to reflux and maintained for3 hours. A short pass column was installed and toluene was distilled(atmospheric pressure, 124 ml) off to remove excess reagent. Aftercooling the remaining toluene was distilled off, which resulted in athick oil. This oil was distilled (90° C., 2 mm Hg) to remove impuritiesand the product crystallized on standing (79.8% yield), mp: 55-58° C.

EXAMPLE 18-Azabicyclo[3.2.1]oct-8-yl([2,1,3]-benzoxadiazol-5-yl)methanone

To a solution of tropane (2.5 g, 20 mmol) in toluene (80 ml) was slowlyadded [2,2,2]-trichloroethyl chloroformate (20 ml, 94.4 mmol) andNa₂CO₃(1.5 g, 14 mmol). The mixture was heated to 110° C. overnight. Thesolution was cooled to room temperature, ethyl acetate (150 ml), water(100 ml) and H₂SO₄ (→pH 2) were added. The organic phase was dried oversodium sulfate, and concentrated under vacuum to yield 9.3 g colorlessoil. The preceding product (3.3 g) was dissolved in THF (50 ml) andmethanol (50 ml), and freshly prepared Zn/Cu (15 g) was added followedby formic acid (5 ml). The mixture was stirred at room temperature for20 minutes before filtering the solids and evaporating the solvent until˜10 ml remained. Concentrated sodium hydroxide solution was added untilpH 10 was reached and the mixture extracted with chloroform (100 ml) andthe organic phase dried over sodium sulfate. Triethylamine (2 ml) wasadded followed by a solution of[2,1,3]-benzoxadiazole-5-carbonylchloride (0.5 g, 2.73 mmol) inchloroform (20 ml), slowly. After stirring the mixture for 20 minutes,water (100 ml) and H₂SO₄ (→pH2) were added and the aqueous phaseextracted with chloroform (100 ml), dried over magnesium sulfate, andconcentrated under vacuum to give an oil. The material was purified bysilica gel chromatography eluting with hexane/ethyl acetate (3:2), togive after crystallization from dicloromethane/MTBE 133 mg of a whitesolid: mp=128-130° C., LC-MS, MH⁺=258; ¹H NMR (300 MHz, CDCl₃) δ 7.92(s, 1H); 7.90 (d, 1H, J=6.3 Hz); 7.52 (d, 1H, J=6.3 Hz); 4.84 (s, 1H);4.06 (s, 1H); 2.06-1.50 ppm (m, 10H).

EXAMPLE 28-([2,1,3]-Benzoxadiazol-5-ylcarbonyl)-8-azabicyclo[3.2.1]octan-3-one

To a solution of tropinone (10 g, 71.8 mmol) in toluene (120 ml) wasslowly added [2,2,2]-trichloroethyl chloroformate (40 ml, 189 mmol) andsodium carbonate (4.0 g, 37.7 mmol). The mixture was heated to 110° C.for 42 hours, the solvent evaporated, water (100 ml) and H₂SO₄ (→pH 2)added and the mixture extracted with ethyl acetate (3×100 ml). Theorganic phase was dried over sodium sulfate, concentrated under vacuumand the residue purified by silica gel chromatography eluting withhexane/ethyl acetate (4:1) to give an oil (12.9 g) which solidified onstanding. To a solution of this product (2.5 g) in THF (40 ml) andmethanol (40 ml) was added freshly prepared Zn/Cu (12 g) and the mixturestirred at room temperature for 1 h. Triethylamine (3 ml) was added, thesolids filtered off and washed with methanol (10 ml), and the solventevaporated. The residue was dissolved in chloroform (80 ml), andtriethylamine (3 ml) was added followed by slow addition of a solutionof [2,1,3]-benzoxadiazole-5-carbonylchloride (1.5 g, 8.2 mmol) inchloroform (20 ml). After stirring the mixture for 1 h, water (100 ml)and H₂SO₄ (→pH2) were added and the aqueous phase extracted withchloroform (100 ml). The combined organics were washed with NaHCO₃solution (100 ml), dried over sodium sulfate, and concentrated undervacuum. The residue was purified by silica gel chromatography elutingwith hexane/ethyl acetate (1:1) to give a solid that was crystallizedfrom dichloromethane/MTBE (1.04 g): mp=164-166° C., LC-MS, MH⁺=272; ¹HNMR (300 MHz, CDCl₃) δ 8.02 (s, 1H); 7.97 (d, 1H, J=9 Hz); 7.57 (d, 1H,J=9 Hz); 5.09 (sb, 1H); 4.44 (sb, 1H); 3.05-1.80 ppm (m, 8H).

EXAMPLE 3 and EXAMPLE 4[2,1,3]-Benzoxadiazol-5-yl(3,3-difluoro-8-azabicyclo[3.2.1]oct-8-yl)methanoneand[2,1,3]-benzoxadiazol-5-yl(3-fluoro-8-azabicyclo[3.2.1]oct-2-en-8-yl)methanone

To a solution of8-([2,1,3]-benzoxadiazol-5-ylcarbonyl)-8-azabicyclo[3.2.1]octan-3-one(0.67 g, 2.45 mmol) in dichloromethane (25 ml) was slowly addeddiethylaminosulfur trifluoride, “DAST” (5 g). The mixture was stirred atroom temperature for 3 days and then slowly poured into a mixture ofNaHCO₃ solution (100 ml) and chloroform (100 ml). The aqueous phase wasextracted with chloroform (100 ml) and the combined organics were driedover sodium sulfate, concentrated under vacuum and the residue purifiedby silica gel chromatography eluting with hexane/ethyl acetate (65:35),to give[2,1,3]-benzoxadiazol-5-yl(3,3-difluoro-8-azabicyclo[3.2.1]oct-8-yl)methanone(0.37 g) after crystallization from dichloromethane/MTBE and as the lesspolar of 2 products: mp=165-166° C., LC-MS, MH⁺=294; ¹H NMR (300 MHz,CDCl₃) δ 7.96-7.93 (m, 2H); 7.54-7.50 (m, 1H); 5.00 (sb, 1H); 4.26 (sb,1H); 2.60-2.05 ppm (m, 8H).

A second more polar product was identified as[2,1,3]-benzoxadiazol-5-yl(3-fluoro-8-azabicyclo[3.2.1]oct-2-en-8-yl)methanoneand was crystallized from dichloromethane/MTBE (0.06 g): mp=133-137° C.,LC-MS, MH⁺=274; ¹H NMR (300 MHz, CDCl₃) δ 8.00-7.87 (m, 2H); 7.53 (d,1H, J=8.7 Hz); 5.70-5.45 (m, 1H); 5.05 (sb, 1H); 4.31(sb, 1H); 3.23-1.45ppm (m, 6H).

EXAMPLE 5endo-[2,1,3]-Benzoxadiazol-5-yl(3-hydroxy-8-azabicyclo[3.2.1]oct-8-yl)methanone

To a solution of tropine (4.0 g, 28.3 mmol) in toluene (50 ml) wasslowly added [2,2,2]-trichloroethyl chloroformate (16 ml, 75.5 mmol) andNa₂CO₃(4.0 g, 37.7 mmol). The mixture was heated to 110° C. for 42hours, the toluene removed under vacuum, water (150 ml) and H₂SO₄ (→pH2) were added, and the mixture extracted with ethyl acetate (2×100 ml).The combined organics were dried over sodium sulfate, concentrated undervacuum and the residue chromatographed on silica gel using hexane/ethylacetate (70:30)→(40:60) to give a white solid (6.0 g). To a solution ofthe preceding product (2.5 g, 8.26 mmol) in THF (50 ml) and methanol (50ml), was added freshly prepared Zn/Cu (15 g) and the mixture stirred atroom temperature for 18 h. The solids were filtered off, the solventevaporated and to the residue, dissolved in DMF (60 ml), were added DMAP(0.98 g, 8 mmol), HOBT (0.54 g, 4 mmol), triethylamine (2 ml),[2,1,3]-benzoxadiazole-5-carboxylic acid (1.31 g, 8 mmol) and EDCI (3 g,15.6 mmol) and the mixture stirred at room temperature for 2 days. TheDMF was evaporated and water (100 ml) and H₂SO₄ (→pH2) were added. Themixture was extracted with chloroform (2×100 ml), the combined organicswashed with NaHCO₃ solution (100 ml), dried over sodium sulfate, andconcentrated under vacuum. The residue was purified by chromatography onsilica gel eluting with THF/chloroform (15:85→25:75), to give a whitesolid (1.25 g) after crystallization from THF/chloroform/MTBE:mp=169-171° C., LC-MS, MH⁺=274; ¹H NMR (300 MHz, CDCl₃) δ 7.94-7.88 (m,2H); 7.54-7.47 (m, 1H); 4.83 (sb, 1H); 4.25 (sb, 1H); 4.09 (sb, 1H);2.40-1.80 ppm (m, 8H).

EXAMPLE 6exo-[2,1,3]-Benzoxadiazol-5-yl(3-hydroxy-8-azabicyclo[3.2.1]oct-8-yl)methanone

To a solution ofendo-8-([2,1,3]-benzoxadiazol-5-ylcarbonyl)-8-azabicyclo[3.2.1]octan-3-ol(0.27 g, 0.98 mmol) in anhydrous THF (10 ml) were added 4-nitro benzoicacid (0.33 g, 2 mmol), triphenylphosphine (0.52 g, 2 mmol) and asolution of diisopropyl azodicarboxylate (0.4 g) in THF (1 ml). Themixture was stirred over night at room temperature, NaHCO₃ solution (50ml) was added and the mixture extracted with ethyl acetate (2×100 ml).The organics were dried over sodium sulfate, concentrated under vacuumand the residue purified by chromatography on silica gel eluting withhexane/ethyl acetate (1:1), to give a white solid (0.45 g). Thepreceding product was suspended in anhydrous methanol (70 ml), asolution of sodium (0.2 g) in anhydrous methanol (50 ml) was added andthe mixture was stirred at room temperature for 0.75 h before addingconc. HCl (0.5 ml) (→pH 3) and evaporating the solvent under vacuum. Thecrude product was purified by silica gel chromatography eluting withTHF/chloroform (30:70), to giveexo-[2,1,3]-benzoxadiazol-5-yl(3-hydroxy-8-azabicyclo[3.2.1]oct-8-yl)methanoneas a white solid after crystallization from chloroform/MTBE (0.11 g):mp=176-177° C., LC-MS, MH⁺=274; ¹H NMR (300 MHz, CDCl₃) δ 7.94-7.90 (m,2H); 7.21 (dd, 1H, J=9.3 and 1.2 Hz); 4.88 (sb, 1H); 4.30-4.10 (m, 2H);4.09 (sb, 1H); 2.20-1.50 ppm (m, 8H).

EXAMPLE 72-Azabicyclo[2.2.1]hept-2-yl([2,1,3]-benzoxadiazol-5-yl)methanone

10% Pd/C (0.25 g) was added to a solution of2-azabicyclo[2.2.1]hept-5-en-3-one in THF (30 ml) and dichloromethane(30 ml) and the mixture hydrogenated at room temperature for 18 h. Thesolids were filtered off, the solvent evaporated under vacuum, theresidue dissolved in THF (60 ml) and lithium aluminum hydride (2 g)added slowly. The mixture was refluxed for 1 h and cooled to +5° C.before adding hexane (60 ml) and concentrated sodium hydroxide solution(4 ml). Celite (2 g) was added and the mixture stirred for 1 h beforefiltering off the solids and washing with THF (10 ml). To the mixturewas added triethylamine (3 ml) and a solution of[2,1,3]-benzoxadiazole-5-carbonylchloride (2 g, 11.0 mmol) indichloromethane (10 ml) and the mixture stirred overnight. Water (100ml) was added, acidified to pH 2 with sulfuric acid and extracted withethyl acetate (2×100 ml). The combined organics were washed withsaturated sodium bicarbonate solution (100 ml), dried (NaSO₄) andevaporated onto silica gel (5 g) and the residue was chromatographed onsilica gel eluting with ethyl acetate/hexane (1:1)→(3:1)→(1:0) to givethe desired product as white crystals (0.28 g) after crystallizationfrom MTBE/hexane: mp=92-93° C., LC-MS, MH⁺=244; ¹H NMR (300 MHz, CDCl₃,rotamers) δ 7.93-7.87 (m, 2H), 7.59-7.54 (m, 1H), 4.79 and 4.17 (s,total 1H), 3.61 and 3.48 (m, total 1H), 3.28 and 3.08 (dd, J=9.3 and 1.5Hz, total 1H), 2.74 and 2.64 (s, total 1H), 1.90-1.47ppm (m, 6H).

EXAMPLE 81-Azabicyclo[2.2.1]hept-1-yl([2,1,3]-benzoxadiazol-5-yl)methanone

The title compound was prepared from 1-azabicyclo[2.2.1]heptane (Org.Lett, 2001, 3(9), 1371-1374) and[2,1,3]-benzoxadiazole-5-carbonylchloride as described for Example 7.The compound was isolated as a white crystalline solid: mp=143-144° C.,LC-MS, MH⁺=244; ¹H NMR (300 MHz, CDCl₃) δ 8.00 (dd, J=1.2 and 1.2 Hz,1H), 7.90 (dd, J=9.3 and 1.2 Hz, 1H), 7.59 (dd, J=1.2 and 9.3 Hz, 1H),4.80 (br s, 1H), 4.16 (br s, 1H), 2.08-1.80 (m, 4H), 1.64-1.50 ppm (m,4H).

EXAMPLE 92-Azabicyclo[2.2.2]oct-2-yl([2,1,3]-benzoxadiazol-5-yl)methanone

Cis-4-Aminocyclohexanecarboxylic acid (2.0 g 13.96 mmol) was heated in aflask with a heat gun for 15 minutes. After cooling to room temperature,THF (70 ml) was added followed by lithium aluminum hydride (4 g), slowlyand portion wise, and the mixture heated at 65° C. for 1 h. The mixturewas cooled, and hexane (70 ml) and sodium hydroxide solution (5 ml) wereadded whilst rapidly stirring. Celite (5 g) was added and the mixturestirred overnight. The solids were removed by filtration and washed withTHF (10 ml). Triethylamine (4 ml) was added followed by a solution of[2,1,3]-benzoxadiazole-5-carbonylchloride (2.0 g, 10.95 mmol) indichloromethane (15 ml) and the mixture was stirred at room temperaturefor 0.3 h. Water (100 ml) was added, acidified to pH 2 with sulfuricacid and extracted with ethyl acetate (2×100 ml). The combined organicswere washed with saturated sodium bicarbonate solution (100 ml), dried(NaSO₄) and evaporated under vacuum. The residue was chromatographed onsilica gel eluting with ethyl acetate/dichloromethane/hexane (40:10:50)to give the desired product as a white solid (2.14 g): mp=138-139° C.,LC-MS, MH⁺=258; ¹H NMR (300 MHz, CDCl₃, rotamers) δ 7.91 (dd, J=1.2 and9.3 Hz, 1H), 7.90 and 7.83 (dd, J=1.2 and 1.2 Hz, total 1H), 7.51 and7.46 (dd, J=1.2 and 9.3 Hz, total 1H), 4.58 and 3.42 (br s, total 1H),3.68-2.64 (m, 2H), 2.12-1.61 ppm (m, 9H).

EXAMPLE 10[2,1,3]-benzoxadiazol-5-yl(2-oxa-5azabicyclo[2.2.1]hept-5-yl)methanone

The title compound was prepared from 2-aza-5-oxabicyclo[2.2.1]heptaneand [2,1,3]-benzoxadiazole-5-carbonylchloride as described for Example7: mp=102-104° C., LC-MS, MH⁺=246; ¹H NMR (300 MHz, CDCl₃) δ 7.98-7.90(m, 2H), 7.58 (dd, J=1.2 and 9.3 Hz, 1H), 5.08 and 4.78 (s, total 1H),4.66 and 4.47 (s, total 1H), 4.05 (m, 1H), 3.89 (m, 1H), 3.73-3.63 (m,1H), 3.52 (s, 1H), 2.06-1.95 ppm (m, 2H).

EXAMPLE 112-Azabicyclo[2.2.1]hept-5-en-2-yl([2,1,3]-benzoxadiazol-5-yl)methanone

Prepared from 2-azabicyclo[2.2.1]hept-5-en-3-one by reducing with LiAlH₄and then coupling the resultant 2-azabicyclo[2.2.1]hept-5-ene with[2,1,3]-benzoxadiazole-5-carbonylchloride as described for Example 7.The title product was isolated as a white solid after crystallizationfrom MTBE/hexane: mp=106-108° C., LC-MS, MH⁺=242.25; ¹H NMR (300 MHz,CDCl₃, rotamers) δ 7.98-7.86 (m, 2H), 7.58-7.53 (m, 1H), 6.60-6.50 (m,1H), 6.36-6.32 (m, 1H), 5.25 and 4.57 (s, total 1H), 3.67-3.62 (m, 1H),3.39 and 3.32 (s, total 1H), 3.03 and 2.70 (both d, J=10.2 and 8.7 Hzrespectively, total 1H), 1.75 ppm (s, 2H).

EXAMPLE 12 and EXAMPLE 13R-2-Azabicyclo[2.2.1]hept-5-en-2-yl([2,1,3]-benzoxadiazol-5-yl)methanoneandS-2-Azabicyclo[2.2.1]hept-5-en-2-yl([2,1,3]-benzoxadiazol-5-yl)methanone

The title compounds were prepared from(R)-2-azabicyclo[2.2.1]hept-5-en-3-one and(S)-2-azabicyclo[2.2.1]hept-5-en-3-one using the procedures describedfor Example 11.

-   R-2-Azabicyclo[2.2.1]hept-5-en-2-yl([2,1,3]-benzoxadiazol-5-yl)methanone:    mp=104-106° C.-   S-2-Azabicyclo[2.2.1]hept-5-en-2-yl([2,1,3]-benzoxadiazol-5-yl)methanone:    mp=104-106° C.

EXAMPLE 14[2,1,3]-Benzoxadiazol-5-yl(5,6-dichloro-2-azabicyclo[2.2.1]hept-2-yl)methanone

Concentrated HCl (3 ml) was added to a rapidly stirred mixture of bleach(20 ml) in dichloromethane at room temperature. The mixture was added toa stirred solution of2-zabicyclo[2.2.1]hept-5-en-2-yl([2,1,3]-benzoxadiazol-5-yl) (0.5 g,2.07 mmol) in dichloromethane (50 ml). The mixture was evaporated andthe residue purified by chromatography on silica gel eluting with ethylacetate/hexane (2:3) to give the title compound as a white solid aftercrystallization from dichloromethane/MTBE: mp=156-157° C., LC-MS,MH⁺=312.16; ¹H NMR (300 MHz, CDCl₃, rotamers) δ 8.02-7.95 (m, 2H), 7.52(dd, J=1.1 and 9.2 Hz, 1H), 4.89 and 4.29 (s, total 1H), 4.24-4.15 (m,2H), 3.72-2.40 4.57 ppm (m, 5H).

II. Biological Methods EXAMPLE 15

In Vivo Electrophysiology

The electrophysiological effects of invention compounds were tested invivo in anesthetized animals according to the following procedures.

Animals are maintained under anesthesia by phenobarbital administeredusing a Hamilton syringe pump. Stimulating and recording electrodes areinserted into the perforant path and dentate gyrus of the hippocampus,respectively. Once electrodes are implanted, a stable baseline of evokedresponses are elicited using single monophasic pulses (100 μs pulseduration) delivered at 3/min to the stimulating electrode. Field EPSPsare monitored until a stable baseline is achieved (about 20-30 min),after which a solution of test compound is injected intraperitoneallyand evoked field potentials are recorded. Evoked potentials are recordedfor approximately 2 h following drug administration or until theamplitude of the field EPSP returns to baseline. In the latter instance,it is common that an iv administration is also carried out with anappropriate dose of the same test compound.

EXAMPLE 2

Inhibition of d-Amphetamine Stimulated Locomotion

Male CD1 mice, 25-30 gm body weight, were brought into the experimentalroom and allowed at least 30 min of acclamation. Each mouse was placedinto the testing enclosure with an infrared beam array thatautomatically monitors the animal's activity. Mice were habituated inthe testing enclosure for 20 min, and then returned to their home cage.Mice were dosed intraperitoneally with test compound in appropriatevehicle 5 minutes before d-Amphetamine injection. Ten minutes afterd-Amphetamine injection, mice were tested for locomotor activity for atotal of 15 minutes. The data was computer collected and expressed as“arbitrary movement units.” All data were analyzed by comparing thegroups treated with the test compound to the vehicle control group.Statistical analysis was performed by ANOVA followed by Dunnet's t-testwhere P less than 0.05 were considered to be significantly different.

While the invention has been described with reference to specificmethods and embodiments, it will be appreciated that variousmodifications may be made without departing from the invention.

1. A compound according to formula A:

wherein: W is oxygen; X, Y and Z are independently selected from thegroup consisting of —N, or —CR, wherein: R is H, —Br, —Cl, —F, —CN,—NO₂, —OR¹, —SR¹, —NR¹ ₂, —C₁-C₆ branched or un-branched alkyl, whichmay be un-substituted or substituted, wherein: R¹ is H, —C₁-C₆ branchedor un-branched alkyl which, may be un-substituted or substituted, n is0, 1, 2, 3, 4, 5 m is 0, 1, 2, 3, 4, 5 p is 1, 2, 3, 4, 5 R² and R³ areeach independently selected from H, a halogen (preferably F), —CN, —NO₂,—OR¹, —SR¹, —NR¹ ₂, CF₃, OH, C═O, a —C₁-C₆ branched or un-branchedalkyl, which may be un-substituted or substituted, a —C₂-C₆ branched orun-branched alkenyl, which may be un-substituted or substituted, a—C₂-C₆ branched or un-branched alkynyl, which may be un-substituted orsubstituted, a —C₃-C₇ cycloalkyl which may be un-substituted orsubstituted, an aryl which may be un-substituted or substituted, aheterocycle which may be un-substituted or substituted, a carboxyalkylwhich may be un-substituted or substituted, a carboxyaryl which may beun-substituted or substituted, a carboxyheteroaryl which may beun-substituted or substituted, a sulfonylalkyl which may beun-substituted or substituted, a sulfonylaryl which may beun-substituted or substituted or a sulfonylheteroaryl which may beun-substituted or substituted, E and F are each independently selectedfrom CH₂m, CR²R³, A, CH₂A, CR²═CR³ or are absent, with the proviso thatE and F are not both absent; G is CR²R³, A, CH₂A, CR²═CR³, CH₂C═O,CH₂CR²R³, or absent, A is O, S, SO, SO₂, C═O or CR²R³; or apharmaceutically acceptable salt thereof.
 2. The compound according toclaim 1 of the formula:

wherein: W is oxygen; X, Y and Z are independently selected from thegroup consisting of —N, or —CR, wherein: R is H, —Br, —Cl, —F, —CN,—NO₂, —OR¹, —SR¹, —NR¹ ₂, —C₁-C₆ branched or un-branched alkyl, whichmay be un-substituted or substituted, wherein: R¹ is H, —C₁-C₆ branchedor un-branched alkyl which, may be un-substituted or substituted, n is0-5 m is 0-5 p is 1-5 R² and R³ are independently selected from H, ahalogen (preferably F), —CN, —NO₂, —OR¹, —SR¹, —NR¹ ₂, CF₃, OH, C═O, a—C₁-C₆ branched or un-branched alkyl, which may be un-substituted orsubstituted, a —C₂-C₆ branched or un-branched alkenyl, which may beun-substituted or substituted, a —C₂-C₆ branched or un-branched alkynyl,which may be un-substituted or substituted, a —C₃-C₇ cycloalkyl whichmay be un-substituted or substituted, an aryl which may beun-substituted or substituted , a heterocycle which may beun-substituted or substituted, a carboxyalkyl which may beun-substituted or substituted, a carboxyaryl which may be un-substitutedor substituted, a carboxyheteroaryl which may be un-substituted orsubstituted, a sulfonylalkyl which may be un-substituted or substituted,a sulfonylaryl which may be un-substituted or substituted or asulfonylheteroaryl which may be un-substituted or substituted, or apharmaceutically acceptable salt thereof.
 3. The compound according toclaim 2 of the formula:

wherein: “W is oxygen, X, Y, and Z are independently selected from thegroup consisting of —N, or —CR, wherein: R is H, —Br, —Cl, —F, —CN,—NO₂, —OR¹, —SR¹, —NR¹ ₂, —C₁-C₆ branched or un-branched alkyl, whichmay be un-substituted or substituted, wherein: R¹ is H, —C₁-C₆ branchedor un-branched alkyl, which, may be un-substituted or substituted, ” nis 0-5 m is 0-5 p is 1-4 and R² and R³ are independently selected fromH, a halogen (preferably F), —CN, —NO₂, —OR¹, —SR¹, —NR¹ ₂, CF₃, OH,C═O, a —C₁-C₆ branched or un-branched alkyl, which may be un-substitutedor substituted, —C₂-C₆ branched or un-branched alkenyl, which may beun-substituted or substituted, —C₂-C₆ branched or un-branched alkynyl,which may be un-substituted or substituted, —C₃-C₇ cycloalkyl, which maybe un-substituted or substituted, an aryl which may be un-substituted orsubstituted, a heterocycle which may be un-substituted or substituted, acarboxyalkyl which may be un-substituted or substituted, a carboxyarylwhich may be un-substituted or substituted, a carboxyheteroaryl whichmay be un-substituted or substituted, a sulfonylalkyl which may beun-substituted or substituted, a sulfonylaryl which may beun-substituted or substituted, a sulfonylheteroaryl which may beun-substituted or substituted, or a pharmaceutically acceptable saltthereof.
 4. The compound according to claim 1 of the formula:

wherein: W is oxygen, X, Y, and Z are independently selected from thegroup consisting of —N, or —CR, wherein: R is H, —Br, —Cl, —F, —CN,—NO₂, —OR¹, —SR¹, —NR¹ ₂, —C₁-C₆branched or un-branched alkyl, which maybe un-substituted or substituted, wherein: R¹ is H, —C₁-C₆branched orun-branched alkyl, which, may be un-substituted or substituted, A is O,S, SO, SO₂, C═O or CR²R³; n is 0-5 m is 1-5 p is 1-5 and R² and R³ areindependently selected from H, a halogen (preferably F), —CN, —NO₂,—OR¹, —SR¹, —NR¹ ₂, CF₃, OH, C═O, a —C₁-C₆ branched or un-branchedalkyl, which may be un-substituted or substituted, —C₂-C₆ branched orun-branched alkenyl, which may be un-substituted or substituted, —C₂-C₆branched or un-branched alkynyl, which may be un-substituted orsubstituted, —C₃-C₇ cycloalkyl, which may be un-substituted orsubstituted, an aryl which may be un-substituted or substituted, aheterocycle which may be un-substituted or substituted, a carboxyalkylwhich may be un-substituted or substituted, a carboxyaryl which may beun-substituted or substituted, a carboxyheteroaryl which may beun-substituted or substituted, a sulfonylalkyl which may beun-substituted or substituted, a sulfonylaryl which may beun-substituted or substituted, a sulfonylheteroaryl which may beun-substituted or substituted, or a pharmaceutically acceptable saltthereof.
 5. The compound according to claim 1 of the formula:

wherein: W is oxygen, X, Y, and Z are independently selected from thegroup consisting of —N, or —CR, wherein: R is H, —Br, —Cl, —F, —CN,—NO₂, —OR¹, —SR¹, —NR¹ ₂, —C₁-C₆ branched or un-branched alkyl, whichmay be un-substituted or substituted, wherein: R¹ is H, —C₁-C₆ branchedor un-branched alkyl, which, may be un-substituted or substituted, A isO, S, SO, SO₂, C═O or CR²R³; n=1-5 m=1-5 p=1-5 and R³ are independentlyselected from H, a halogen (preferably F), —CN, —NO₂, —OR¹, —SR¹, —NR¹₂, CF₃, OH, C═O, a —C₁-C₆ branched or un-branched alkyl, which may beun-substituted or substituted, —C₂-C₆ branched or un-branched alkenyl,which may be un-substituted or substituted, —C₂-C₆ branched orun-branched alkynyl, which may be un-substituted or substituted, —C₃-C₇cycloalkyl, which may be un-substituted or substituted, an aryl whichmay be un-substituted or substituted, a heterocycle which may beun-substituted or substituted, a carboxyalkyl which may beun-substituted or substituted, a carboxyaryl which may be un-substitutedor substituted, a carboxyheteroaryl which may be un-substituted orsubstituted, a sulfonylalkyl which may be un-substituted or substituted,a sulfonylaryl which may be un-substituted or substituted, asulfonylheteroaryl which may be un-substituted or substituted, or apharmaceutically acceptable salt thereof.
 6. The compound according toFormula A of claim 1 where W is O; X, Y and Z are CR; R is F, Br, Cl, CNor NO₂; E is CH₂m or CH₂A; F is CH₂m or CR²R³; R² and R³ are H; G isCH₂A; A is O; m is 1; n is 0; and p is
 1. 7. The compound according toFormula A of claim 1 where W is O; X, Y and Z are CR; R is H; E and Fare CH₂m; G is CH2A; A is O; m is 1; n is 0; and p is
 1. 8. The compoundaccording to Formula A of claim 1 where W is O; X, Y and Z are CR; R isH; E is CH₂A; F is CH₂m; G is CH₂A; A is O; m is 1; n is 0; and p is 1.9. The compound according to Formula A of claim 1 where W is O; X, Y andZ are CR; R is H; E is CH₂m; F is CR²R³; R² and R³ are H; G is CH₂A; Ais O; m is 2; n is 0; and p is
 1. 10. The compound according to FormulaI of claim 2 which is:8-Azabicyclo[3.2.1]oct-8-yl([2,1,3]-benzoxadiazol-5-yl)methanone8-([2,1,3]-Benzoxadiazol-5-ylcarbonyl)-8-azabicyclo[3.2.1]octan-3-one[2,1,3]-Benzoxadiazol-5-yl(3,3-difluoro-8-azabicyclo[3.2.1]oct-8-yl)methanoneendo-[2,1,3]-Benzoxadiazol-5-yl(3-hydroxy-8-azabicyclo[3.2.1]oct-8-yl)methanoneexo-[2,1,3]-Benzoxadiazol-5-yl(3-hydroxy-8-azabicyclo[3.2.1]oct-8-yl)methanone2-Azabicyclo[2.2.1]hept-2-yl([2,1,3]-benzoxadiazol-5-yl)methanone1-Azabicyclo[2.2.1]hept-1-yl([2,1,3]-benzoxadiazol-5-yl)methanone2-Azabicyclo[2.2.2]oct-2-yl([2,1,3]-benzoxadiazol-5-yl)methanone or[2,1,3]-Benzoxadiazol-5-yl(5,6-dichloro-2-azabicyclo[2.2.1]hept-2-yl)methanone.11. The compound according to Formula II of claim 3 which is:[2,1,3]-Benzoxadiazol-5-yl(3-fluoro-8-azabicyclo[3.2.1]oct-2-en-8-yl)methanone2-Azabicyclo[2.2.1]hept-5-en-2-yl([2,1,3]-benzoxadiazol-5-yl)methanoneR-2-Azabicyclo[2.2.1]hept-5-en-2-yl([2,1,3]-benzoxadiazol-5-yl)methanoneorS-2-Azabicyclo[2.2.1]hept-5-en-2-yl([2,1,3]-benzoxadiazol-5-yl)methanone.12. The compound according to Formula IV of claim 5 which is:[2,1,3]-Benzoxadiazol-5-yl(2-oxa-5azabicyclo[2.2.1]hept-5-yl)methanone.13. A pharmaceutical composition comprising an effective amount of acompound according to any of claims 1-2 in combination with apharmaceutically acceptable carrier, additive or excipient.
 14. Thecomposition according to claim 13 wherein said compound comprises about0.5% to about 75% by weight of said composition and said carrier,additive or excipient comprises about 25% to about 95.5% of saidcomposition.